Ambulatoria Za Specializirana Medicinska Pomosht-Grupova Praktika Po Dermatologia Clinica Evroderma OOD
- Address
- lock Available on a paid plan
Dermatology Research in Immune System Diseases
At Ambulatoria Za Specializirana Medicinska Pomosht-Grupova Praktika Po Dermatologia Clinica Evroderma OOD in Sofia, Bulgaria, clinical research in dermatology focuses on immune-driven skin conditions such as atopic dermatitis, hidradenitis suppurativa, and psoriasis. These studies are designed to evaluate how well new and existing therapies control symptoms, maintain response over time, and improve patient safety and tolerability.
- Testing treatment adjustments for atopic dermatitis to improve disease control and support better long-term outcomes
- Evaluating therapy effectiveness in hidradenitis suppurativa, with attention to sustained response and loss of benefit over time
- Assessing new options for moderate to severe plaque psoriasis to better manage chronic inflammatory skin disease
This research area reflects a strong interest in therapies that target the underlying immune processes behind persistent skin inflammation.
Studies in Skin and Connective Tissue Diseases
The site also supports clinical trials in skin and connective tissue diseases, with a clear emphasis on vitiligo and related pigment disorders. Research here explores whether topical and oral treatments can improve repigmentation, extend treatment benefit, and offer safe options for both adults and children.
- Investigating treatment effectiveness in nonsegmental vitiligo for adult participants
- Evaluating a cream-based therapy for pediatric vitiligo to support skin repigmentation
- Studying long-term safety and tolerability in vitiligo care
These trials highlight ongoing efforts to improve both visible skin outcomes and the overall treatment experience for people living with chronic pigment loss.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Incyte Corp.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ambulatoria Za Specializirana Medicinska Pomosht-Grupova Praktika Po Dermatologia Clinica Evroderma OOD
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa | Novartis Pharma AG | Phase III | Not Recruiting | Mar 2020 | Jun 2026 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apremilast | 1 | Unknown | 2024-05-07 | 2024-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.